Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary obtains drug registration certificate for Bupivacaine Hydrochloride Injection.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that recently, its subsidiary Hubei Tianyao Pharmaceuticals Co., Ltd. received the Drug Registration Certificate for Bupivacaine Hydrochloride Injection approved and issued by the National Medical Products Administration. Bupivacaine Hydrochloride Injection is indicated for local infiltration anesthesia, peripheral nerve block, and intraspinal block.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that recently, its subsidiary Hubei Tianjin Tianyao Pharmaceuticals Co., Ltd. received the Drug Registration Certificate for Bupivacaine Hydrochloride Injection approved and issued by the National Medical Products Administration. Bupivacaine Hydrochloride Injection is indicated for local infiltration anesthesia, peripheral nerve block, and intraspinal block.
Related Articles
SSY GROUP (02005) repurchased 3.2 million shares for HK$8.3707 million on September 14.
HSBC HOLDINGS (00005) repurchased 321,600 shares for approximately HK$52.2423 million on September 11.
WuXi AppTec (02359) issues 52,800 shares upon conversion of zero-coupon convertible bonds.
SSY GROUP (02005) repurchased 3.2 million shares for HK$8.3707 million on September 14.
HSBC HOLDINGS (00005) repurchased 321,600 shares for approximately HK$52.2423 million on September 11.
WuXi AppTec (02359) issues 52,800 shares upon conversion of zero-coupon convertible bonds.
RECOMMEND
